alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Exhibit 32.2


                            CERTIFICATION PURSUANT TO
                             18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

         In connection with the Annual Report on Form 20-F of American Israeli
Paper Mills Limited (the "Company") for the year ended December 31, 2004 as
filed with the Securities and Exchange Commission on the date hereof (the
"Report"), the undersigned, Israel Eldar, Chief Financial Officer of the
Company, certifies, pursuant to 18 U.S.C. sec. 1350, as adopted pursuant to sec.
906 of the Sarbanes-Oxley Act of 2002, that:

                  (1) The Report fully complies with the requirements of section
         13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

                  (2) The information contained in the Report fairly presents,
         in all material respects, the financial condition and result of
         operations of the Company.

Date: September 29, 2005                     /s/ Israel Eldar
                                             -----------------------------------
                                             Israel Eldar
                                             Chief Financial Officer
exhibit107-psuawardagree






EXHIBIT D  Amendment to  Outstanding 2021 and 2022 Performance Stock Unit Awards  under the LivaNova PLC 2015 Incentive Award Plan  This amendment (the “Amendment”), dated as of June ____, 2022, hereby modifies each 2021  and 2022 performance stock unit (“PSU”) award agreement evidencing a currently outstanding  PSU award under the LivaNova PLC 2015 Incentive Award Plan (as permitted pursuant to  Section 11.7 of the LivaNova PLC 2015 Incentive Award Plan) as follows:  1. Section 2.2(d) of each outstanding PSU award agreement is hereby deleted and replaced with the following: “PSUs (and the associated Dividend Equivalents), to the extent not forfeited or otherwise vested immediately prior to the occurrence of a Change in Control, may be assumed or an equivalent Award substituted by the successor corporation or a parent or subsidiary of the successor corporation, subject to the Participant’s continuous employment with the Company or a Subsidiary through such Change in Control.  For purposes of this Section 2.2(d), the PSUs (and the associated Dividend Equivalents) shall be considered assumed or substituted if, following the Change in Control, the applicable assumed or substituted Award (i) meets the requirements set forth in Section 13.2(f) of the Sub-Plan and (ii) the Performance Criteria and Performance Goals applicable to the PSUs (as set forth in the Grant Notice) as of immediately prior to the Change in Control are equitably adjusted in connection with such Change in Control as determined to be appropriate by the Administrator in its sole discretion.” 2. A new Section 2.2(e) shall be added to each outstanding PSU award agreement and shall read as follows: “In the event of a Change in Control where the PSUs (and the associated Dividend Equivalents) are not assumed or substituted by the successor corporation or parent or subsidiary of the successor corporation, then the PSUs (and the associated Dividend Equivalents), to the extent not forfeited or otherwise vested immediately prior to such Change in Control, shall become vested (assuming 100% achievement or funding, as applicable, as set forth in the Grant Notice) immediately prior to, but subject to the consummation of, such Change in Control, subject to the Participant’s continuous employment with the Company or a Subsidiary through such Change in Control.” 3. Except as expressly amended by this Amendment, all terms and conditions of the Plan and the outstanding Awards thereunder shall remain in full force and effect. 4. This Amendment shall be governed by and construed in accordance with the laws of the State of Delaware, without reference to principles of conflict of laws. 





 






2  LIVANOVA PLC  Name:  Title:  /s/ Trui Hebbelinck
Exhibit 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

Pursuant to 18 U.S.C.
§1350, as adopted pursuant to

§906 of the Sarbanes-Oxley Act of 2002

In connection with the filing with the Securities and Exchange Commission of the Annual Report of Hemagen Diagnostics, Inc., the
Company, on Form 10-K for the period ending September 30, 2010, (the Report), I, William P. Hales, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to § 906 of
the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:



| | 1. | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
| | -- | ---------------------------------------------------------------------------------------------------------------------



| | 2. | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
| | -- | ----------------------------------------------------------------------------------------------------------------------------------------------------

|                        |  |  |  |                                                        
|----------------------- |  |  |  | -------------------------------------------------------
|                        |  | 
|Date: December 23, 2010 |  |  |  | /s/    WILLIAM P.
HALES                                
|                        |  |  |  | William P. Hales
 President and Chief Executive
Officer
#### The People of the State of New York, Respondent, v Philip George, Appellant.

Submitted December 27, 2010;

decided January 6, 2011

Motion for an extension of the time within which to apply for permission to appeal pursuant to CPL 460.20 dismissed as untimely.

Judge Pigott taking no part.
#### The People of the State of New York, Respondent, v Steven Talley, Appellant.

[977 NYS2d 526]

Appeal from a judgment of the Supreme Court, Erie County (Gerald J. Whalen, J.), rendered July 11, 2011. The judgment convicted defendant, upon his plea of guilty, of attempted criminal possession of a controlled substance in the fourth degree.

It is hereby ordered that the judgment so appealed from is unanimously affirmed.

Memorandum: On appeal from a judgment convicting him upon his plea of guilty of attempted criminal possession of a controlled substance in the fourth degree (Penal Law §§ 110.00, 220.09 [1]), defendant contends that his waiver of the right to appeal is unenforceable and that his sentence is unduly harsh and severe. The record demonstrates, however, that Supreme Court “engage [d] the defendant in an adequate colloquy to ensure that the waiver of the right to appeal was a knowing and voluntary choice” *(People v Burt,*101 AD3d 1729, 1730 [2012], *lv denied*20 NY3d 1060 [2013] [internal quotation marks omitted]), and that defendant also signed a written waiver of the right to appeal (see *People v Pulley,*107 AD3d 1560, 1561 [2013], *lv denied*21 NY3d 1076 [2013]). We thus conclude that the waiver is enforceable and that defendant is thereby foreclosed from challenging the severity of his sentence (see *People v Lopez,*6 NY3d 248, 256 [2006]; *People v Suttles,*107 AD3d 1467, 1468 [2013], *lv denied*21 NY3d 1046 [2013]). Present — Scudder, PJ., Smith, Peradotto, Lindley and Sconiers, JJ.
{"agency":"NIGC","generated":"2017-10-26 14:22:18","items":[{"id":"1","parent":null,"text":"Reporting Quarter","due":null,"due_date":"2012\/10\/15","fields":[{"type":"select","name":"2-1-year","label":"Reporting Year","options":[{"label":"2011","value":"2011"},{"label":"2012","value":"2012"},{"label":"2013","value":"2013"},{"label":"2014","value":"2014"},{"label":"2015","value":"2015"},{"label":"2016","value":"2016"},{"label":"2017","value":"2017"}],"value":"2017"},{"type":"select","name":"2-1-quarter","label":"Reporting Quarter","options":[{"label":"Q1","value":"Q1"},{"label":"Q2","value":"Q2"},{"label":"Q3","value":"Q3"},{"label":"Q4","value":"Q4"}],"value":"Q4"}],"multiple":false},{"id":"1-1","parent":"1","text":"Ten Oldest Requests","due":null,"due_date":"2012\/10\/15","fields":[{"type":"select","name":"2-1-1-oldest","label":"Ten Oldest","options":[{"label":"0","value":"0"},{"label":"1","value":"1"},{"label":"2","value":"2"},{"label":"3","value":"3"},{"label":"4","value":"4"},{"label":"5","value":"5"},{"label":"6","value":"6"},{"label":"7","value":"7"},{"label":"8","value":"8"},{"label":"9","value":"9"},{"label":"10","value":"10"}],"value":"10"}],"multiple":false},{"id":"1-3","parent":"1","text":"","due":null,"due_date":"2012\/10\/15","fields":[{"type":"select","name":"2-1-3-closed","label":"Ten Oldest Closed","options":[{"label":"0","value":"0"},{"label":"1","value":"1"},{"label":"2","value":"2"},{"label":"3","value":"3"},{"label":"4","value":"4"},{"label":"5","value":"5"},{"label":"6","value":"6"},{"label":"7","value":"7"},{"label":"8","value":"8"},{"label":"9","value":"9"},{"label":"10","value":"10"}],"value":"9"}],"multiple":false},{"id":"1-2","parent":"1","text":"FOIA Requests Information","due":null,"due_date":"2012\/08\/21","fields":[{"type":"text","name":"2-1-2-component","label":"Component","options":[],"value":["NIGC"]},{"type":"text","name":"2-1-2-received","label":"Received","options":[],"value":["10"]},{"type":"text","name":"2-1-2-processed","label":"Processed","options":[],"value":["12"]},{"type":"text","name":"2-1-2-backlog","label":"Backlog","options":[],"value":["16"]}],"multiple":true}],"year":"2017","quarter":"Q4"}
EXHIBIT 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

AND CHIEF FINANCIAL OFFICER

PURSUANT TO

SECTION 906 OF THE
SARBANES-OXLEY ACT OF 2002

(18 U.S.C. 1350)

In connection with the Quarterly Report on Form 10-Q of Wells Real Estate Fund II-OW (the Registrant) for the quarterly period ended June 30, 2006, as filed with the Securities and Exchange Commission
(the Report), the undersigned, Leo F. Wells, III, Chief Executive Officer of the corporate General Partner of the Registrant, and Douglas P. Williams, Chief Financial Officer of the corporate General Partner of the Registrant, hereby
certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. 1350), that, to the best of our knowledge and belief:



| | (1) | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and
| | --- | ---------------------------------------------------------------------------------------------------------------------



| | (2) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.
| | --- | -------------------------------------------------------------------------------------------------------------------------------------------------------



|                                                           
|-----------------------------------------------------------
|                                                           
|/S/    LEO F. WELLS,
III                                   
|Leo F. Wells, III Chief
Executive Officer August 10, 2006  
|                                                           
|/S/    DOUGLAS P.
WILLIAMS                                 
|Douglas P. Williams Chief Financial Officer August 10, 2006
FI L ED U.S. COURT OF A P P E A LS E LE V E N T H C IR C U IT MAY 5, 2005 THOMAS K. KAH

N CL ERK [DO NOT PUBLISH] IN THE UN ITED STATES COURT OF APPEALS FO R T HE EL EV EN TH CIRC UI T

____ ____ ____ ____ ____ __ N o. 04- 1605 2 Non-A rgum ent Calendar

____ ____ ____ ____ ____ ___ D . C. D oc ke t N o. 99- 0019 4- CR -0 0l UNITED STAT ES OF AMERIC A, Plaintiff-Appellee, ve rs us DANIEL-JAY D. MAHONE, D ef en dant- Appe llant.

____ ____ ____ ____ ____ ____ ____ ____ ____ ____ Appe al f ro m the U nit ed

S ta te s D istri ct

Co urt f o r t h e S o u t h e rn D i s t r i c to f

A l ab a ma

____ ____ ____ ____ ____ ____ ____ ____ ____ ____ (M ay 5, 200 5) Befo re TJ OFLAT, DU BINA an d C ARNES, Cir cu it Ju dg es . PE R CU RIA M:Peter

J. Ma dden, appointed cou nsel for D aniel-Jay D. Mahone in this direct cr im ina l a

ppe al , ha s m ove d to w ith dr awf ro m f urthe r re pr es en ta tio n of

the ap pe llant and f

ile d abr ie f pur suant t o A nde rs v. Ca lif or nia , 386 U . S. 738 , 87 S . Ct . 1396 , 18 L . E d. 2d 4 93 ( 1967 ). O ur ind ep en de nt r ev ie wof

the e nti re r ec or d r ev ea ls that counsel * s a sse ssm en t of the r el at ive m er it of

the appe al is co rr ec t. Be ca use ind ep en de nt e xa m ina tio n of the e nti re r ec or d r ev ea ls n o arg uable iss ue s of m er it, counsel * s m oti on t o w ith dr awis GRANTED, an d M ah one * s c onvi ct ion s and sentences are AF FIRMED .

2
{"agency":"NIGC","generated":"2021-07-26 19:46:28","items":[{"id":"1","parent":null,"text":"Reporting Quarter","due":null,"due_date":"2012\/10\/15","fields":[{"type":"select","name":"2-1-year","label":"Reporting Year","options":[{"label":"2011","value":"2011"},{"label":"2012","value":"2012"},{"label":"2013","value":"2013"},{"label":"2014","value":"2014"},{"label":"2015","value":"2015"},{"label":"2016","value":"2016"},{"label":"2017","value":"2017"},{"label":"2018","value":"2018"},{"label":"2019","value":"2019"},{"label":"2020","value":"2020"}],"value":"2021"},{"type":"select","name":"2-1-quarter","label":"Reporting Quarter","options":[{"label":"Q1","value":"Q1"},{"label":"Q2","value":"Q2"},{"label":"Q3","value":"Q3"},{"label":"Q4","value":"Q4"}],"value":"Q3"}],"multiple":false},{"id":"1-1","parent":"1","text":"Ten Oldest Requests","due":null,"due_date":"2012\/10\/15","fields":[{"type":"select","name":"2-1-1-oldest","label":"Ten Oldest","options":[{"label":"0","value":"0"},{"label":"1","value":"1"},{"label":"2","value":"2"},{"label":"3","value":"3"},{"label":"4","value":"4"},{"label":"5","value":"5"},{"label":"6","value":"6"},{"label":"7","value":"7"},{"label":"8","value":"8"},{"label":"9","value":"9"},{"label":"10","value":"10"}],"value":"3"}],"multiple":false},{"id":"1-3","parent":"1","text":"","due":null,"due_date":"2012\/10\/15","fields":[{"type":"select","name":"2-1-3-closed","label":"Ten Oldest Closed","options":[{"label":"0","value":"0"},{"label":"1","value":"1"},{"label":"2","value":"2"},{"label":"3","value":"3"},{"label":"4","value":"4"},{"label":"5","value":"5"},{"label":"6","value":"6"},{"label":"7","value":"7"},{"label":"8","value":"8"},{"label":"9","value":"9"},{"label":"10","value":"10"}],"value":"2"}],"multiple":false},{"id":"1-2","parent":"1","text":"FOIA Requests Information","due":null,"due_date":"2012\/08\/21","fields":[{"type":"text","name":"2-1-2-component","label":"Component","options":[],"value":["NIGC"]},{"type":"text","name":"2-1-2-received","label":"Received","options":[],"value":["4"]},{"type":"text","name":"2-1-2-processed","label":"Processed","options":[],"value":["4"]},{"type":"text","name":"2-1-2-backlog","label":"Backlog","options":[],"value":["2"]}],"multiple":true}],"year":"2021","quarter":"Q3"}
Exhibit 32.1

CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER

Pursuant to 18 U.S.C. § 1350, as created by
Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of ImmunoCellular Therapeutics, Ltd. (the Company) hereby certifies that, to his knowledge:

(i) The Quarterly Report on Form 10-Q of the Company for the fiscal quarter ended June 30, 2008 (the Report) fully
complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

(ii) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

|                      |  |  |  |     |  |                  |  |                                                                       
|--------------------- |  |  |  | --- |  | ---------------- |  | ----------------------------------------------------------------------
|                      |  |  | 
|Date: August 13, 2008 |  |  |  | By: |  | /s/ Manish Singh
|                      |  |  |  |     |  |                  |  | Name: Manish Singh, Ph.D. Title: President and Chief
Executive Officer
NOT FOR PUBLICATION

UNITED STATES COURT OF APPEALS

FOR THE NINTH CIRCUIT

LI WANG, 

Petitioner, 

 v. 

WILLIAM P. BARR, Attorney General, 

Respondent.

No. 19-70531 

Agency No. A206-340-086 

MEMORANDUM*

On Petition for Review of an Order of the

Board of Immigration Appeals

Submitted December 2, 2020**

Before: WALLACE, CLIFTON, and BRESS, Circuit Judges.

Li Wang, a native and citizen of China, petitions for review of the Board of 

Immigration Appeals’ order dismissing her appeal from an immigration judge’s 

decision denying her application for asylum, withholding of removal, and relief 

under the Convention Against Torture (“CAT”). We have jurisdiction under 8 

U.S.C. § 1252. We review factual findings for substantial evidence, applying the 

* This disposition is not appropriate for publication and is not precedent 

except as provided by Ninth Circuit Rule 36-3.

** The panel unanimously concludes this case is suitable for decision 

without oral argument. See Fed. R. App. P. 34(a)(2).

FILED

DEC 9 2020

MOLLY C. DWYER, CLERK

U.S. COURT OF APPEALS
2 19-70531 

standards governing adverse credibility determinations created by the REAL ID 

Act. Shrestha v. Holder, 590 F.3d 1034, 1039-40 (9th Cir. 2010). We deny the 

petition for review. 

Substantial evidence supports the adverse credibility determination based on

Wang’s omission of her mother’s threat from her original and amended written 

asylum application. See id. at 1048 (adverse credibility determination reasonable 

under “the totality of circumstances”); see also Silva-Pereira v. Lynch, 827 F.3d 

1176, 1185-86 (9th Cir. 2016) (prior omission supported adverse credibility 

determination where new allegations were more compelling). Wang’s 

explanations do not compel a contrary conclusion. See Lata v. INS, 204 F.3d 1241, 

1245 (9th Cir. 2000). Substantial evidence also supports the finding that Wang did 

not present corroborative evidence that would otherwise establish her eligibility for 

relief. See Garcia v. Holder, 749 F.3d 785, 791 (9th Cir. 2014) (petitioner’s 

documentary evidence was insufficient to independently support claim). Thus, in 

the absence of credible testimony, Wang’s asylum and withholding of removal 

claims fail. See Farah v. Ashcroft, 348 F.3d 1153, 1156 (9th Cir. 2003).

Finally, substantial evidence supports the BIA’s denial of Wang’s CAT 

claim because it was based on the same evidence found not credible, and Wang

does not point to any other evidence in the record that compels the conclusion that 

it is more likely than not she would be tortured by or with the consent or 
3 19-70531 

acquiescence of the government if returned to China. See Shrestha, 590 F.3d at 

1048-49.

PETITION FOR REVIEW DENIED.
97-848.

#### In re Guardianship of Bolin.

Miami App. No. 96CA30. This cause is pending before the court as a discretionary appeal. Upon consideration of appellant’s application for dismissal,

IT IS ORDERED by the court that the application for dismissal be, and hereby is, granted.

ACCORDINGLY, IT IS FURTHER ORDERED by the court that this cause be, and hereby is, dismissed.
[Federal Register Volume 74, Number 109 (Tuesday, June 9, 2009)]
[Notices]
[Page 27350]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E9-13351]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Application

    Pursuant to Sec.  1301.33(a) of Title 21 of the Code of Federal 
Regulations (CFR), this is notice that on March 18, 2009, Norac Inc., 
405 S. Motor Avenue, P.O. Box 577, Azusa, California 91702-3232, made 
application by letter to the Drug Enforcement Administration (DEA) to 
be registered as a bulk manufacturer of Nabilone (7379), a basic class 
of controlled substance listed in schedule II.
    The company plans to manufacture bulk controlled substances for use 
in product development and for distribution to its customers.
    Any other such applicant, and any person who is presently 
registered with DEA to manufacture such a substance, may file comments 
or objections to the issuance of the proposed registration pursuant to 
21 CFR 1301.33(a).
    Any such written comments or objections should be addressed, in 
quintuplicate, to the Drug Enforcement Administration, Office of 
Diversion Control, Federal Register Representative (ODL), 8701 
Morrissette Drive, Springfield, Virginia 22152; and must be filed no 
later than August 10, 2009.

    Dated: June 3, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. E9-13351 Filed 6-8-09; 8:45 am]
BILLING CODE 4410-09-P
**Exhibit 32**

**CERTIFICATION PURSUANT TO18 U.S.C. SECTION 1350,AS ADOPTED PURSUANT TOSECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection withthe Annual Report of Warren Resources, Inc. (the “Company”) on Form 10-Kfor the year ending December 31, 2005 as filed with the Securities andExchange Commission on the date hereof (the “report”), we, Norman F. Swantonand Timothy A. Larkin, Chairman and Chief Executive Officer and Executive VicePresident and Chief Financial Officer, respectively, of the registrant,certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of theSarbanes-Oxley Act of 2002, that to our knowledge:

(1)   The reportfully complies with the requirements of section 13(a) or 15(d) of theSecurities Exchange Act of 1934, as amended; and

(2)   The information contained in the reportfairly presents, in all material respects, the financial condition and resultsof operations of the registrant.

| March 8, 2006                                   |   |   |
|------------------------------------------------------|--------|--------|
| /s/ Norman F. Swanton                                |   |   |
| Norman F. Swanton                                    |   |   |
| Chairman and Chief Executive Officer                 |   |   |
| /s/ Timothy A. Larkin                                |   |   |
| Timothy A. Larkin                                    |   |   |
| Executive Vice President and Chief Financial Officer |   |   |

 

----